Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Figure 2 | BMC Cancer

Figure 2

From: Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Figure 2

Kaplan-Meier survival curves comparing subgroups of patients. (A) Comparing the subgroup of patients with an intermediate prognostic Heng factor score and (B) the group of patients with no previous treatment, on the basis of metabolic response or lack of metabolic response (metabolic stable disease and metabolic progress) to 14 days of treatment with tyrosine kinase inhibitors as reflected in TLG2.5.

Back to article page